Alpha Tau Is Building the Local Answer to Pancreatic Cancer’s Systemic Breakthrough
After encouraging early pancreatic data, demand for Alpha DaRT helped quadruple its IMPACT study from 12 patients to 48 as the company moves toward a pivotal trial.
Days after the FDA approved the most significant pancreatic cancer drug in years, Alpha Tau Medical Ltd. (NASDAQ: DRTS) completed enrollment in a pancreatic cancer study that had grown to four times its original size. Following encouraging results in Alpha Tau's earlier pancreatic cancer studies, demand for IMPACT became so strong that the study was expanded three times, ultimately quadrupling from 12 patients to 48. The timing is notable because the two developments sit on opposite, potentially complementary sides of pancreatic cancer treatment. On August 26, the agency granted approval to Rasonque (daraxonrasib), the first broad RAS-targeted medicine from Revolution Medicines that nearly doubled median overall survival in previously treated metastatic disease. It is a landmark moment for systemic therapy. But pancreatic cancer is increasingly understood as a disease requiring both systemic control and local tumor control, and Alpha Tau is now testing whether a one-time local treatment can be added directly to the tumor alongside full-dose systemic therapy.
Rasonque works by targeting multiple forms of the RAS protein, a key driver of tumor growth, and circulates through the bloodstream to attack cancer cells throughout the body. In the Phase 3 RASolute 302 trial, patients on daraxonrasib reached a median overall survival of 13.2 months compared with 6.7 months on standard chemotherapy. But even as systemic therapies improve, pancreatic tumors themselves continue to create severe local problems, including biliary obstruction, pain and compression of surrounding tissue, that drugs traveling through the bloodstream are not designed to address directly.
The medical community appears to recognize this. In August 2026, the American Society for Radiation Oncology published an updated guideline in Practical Radiation Oncology that expanded its radiation therapy recommendations across nearly every pancreatic cancer setting, from resectable and borderline resectable disease to locally advanced, recurrent and even oligometastatic cases. The update builds on ASTRO’s 2019 guidance and reflects a growing consensus that local treatment plays a distinct and necessary role even as systemic options advance.
Alpha DaRT, Alpha Tau’s therapy, takes a fundamentally different approach from both systemic drugs and conventional external-beam radiation. Tiny radium-224 sources are placed directly inside the tumor, often through endoscopic ultrasound, the same workflow gastroenterologists already use. As the radium decays it releases short-range alpha particles that damage nearby cancer cells while traveling too short a distance to reach surrounding healthy tissue. Treatment is delivered in a single outpatient session.
The early pancreatic cancer data has been encouraging. At the 2026 ASCO Annual Meeting, Alpha Tau presented a pooled analysis across three prospective studies involving 58 patients with locally advanced or metastatic disease. Patients treated after first-line chemotherapy reached median overall survival of 11.2 months in metastatic disease and 11.1 months in locally advanced disease, measured from enrollment, against historical benchmarks of four to six months for second-line metastatic treatment. Adverse events occurred in 36% of patients, with Grade 3 or higher events in 9%. All resolved, with no treatment-related deaths and no chronic toxicity. Earlier, at Digestive Disease Week 2026, Alpha Tau reported 100% local disease control in the 19 evaluable patients from its Hadassah Medical Center trials, meaning every evaluable patient’s tumor either shrank or stopped growing. These pancreatic findings come from small, early-stage patient cohorts, and Alpha DaRT remains investigational for pancreatic cancer, with no regulatory approval for that use.
Alpha Tau is now testing this approach alongside front-line chemotherapy in the United States. Its multicenter IMPACT study, which was originally approved for 12 patients and expanded three times, including a third expansion requested by participating clinical sites, has completed enrollment at 48 patients across 10 centers in the United States, Canada and Israel. The study includes patients with locally advanced and metastatic disease receiving either mFOLFIRINOX or gemcitabine plus Abraxane. Initial data is targeted for early 2027 and is expected to help inform the design of a planned pivotal study. IMPACT anchors a broader global pancreatic cancer program that also includes the ACAPELLA trial in France and a University of Verona study evaluating percutaneous delivery.
Pancreatic cancer is only one front. Alpha Tau holds FDA Breakthrough Device Designations covering squamous cell carcinoma of the skin and oral cavity and, separately, recurrent glioblastoma. Its ReSTART pivotal trial in recurrent skin cancer completed enrollment at 88 patients and submitted its first Pre-Market Approval module to the FDA in January 2026. Japan granted marketing approval in February 2026, Alpha DaRT's first regulatory approval outside Israel. And a licensed manufacturing facility in Hudson, New Hampshire, is designed for a nameplate capacity of roughly 400,000 Alpha DaRT sources for local use. Large pharma has spent more than $8 billion acquiring targeted radiation platforms over the past three years, all systemic approaches, a signal that the broader radiation-oncology space has attracted serious strategic interest.
Pancreatic cancer appears to be entering an era where better systemic drugs and better local treatments are used together, each addressing a dimension of the disease the other cannot. The ASTRO guideline update and the Rasonque approval, arriving weeks apart, point in that direction. Importantly, Alpha Tau is developing Alpha DaRT not as a replacement for these systemic advances, but as a one-time local addition to full-dose systemic therapy, potentially allowing the approach to remain relevant as the systemic standard of care evolves. Alpha Tau is positioned on the local-treatment side of that equation, with a growing clinical dataset, a regulatory footprint that now includes the United States, Japan and Israel and a manufacturing base built for the scale the opportunity could require.
Recent News Highlights from Alpha Tau Medical Ltd. (Nasdaq: DRTS)
Read this Next >>
Daraxonrasib Approval Shifts Pancreatic Oncology from Cytotoxic Care to RAS-Targeted Precision
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from a related party on behalf of Alpha Tau Medical Ltd. (the "Issuer") for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article has not been reviewed or approved by the Issuer prior to publication and should not be considered an official communication of the Issuer.